News

The application seeks to broaden the existing marketing authorisation to include daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed

The CMA has provisionally found that Concordia overcharged the NHS by millions for the thyroid drug by increasing the price of a pack of liothyronine tablets from about £4.46 prior to its

Tasigna has also been approved for the treatment of pediatric patients with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib. Tasigna said to be the

Hemogenyx will leverage the experience of researchers at the University of Oxford in administering certain biologics to stem cells to attempt to accelerate and improve the engraftment of

 Key points from the advice are: The application can be submitted as a hybrid application (under article 10(3) of Directive 2001/83/EC), bridging to the well-established safety and efficacy

The UK-based Summit is likely to report results from the initial 24-week dosing period in the first quarter of 2018 which are anticipated to contain data from muscle biopsies,

Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that can

As a result of the merger, Can-Fite’s ownership of OphthaliX, immediately post-merger, became approximately 8% of the outstanding shares. As part of the merger, Can-Fite cancelled OphthaliX’s prior

The companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals and its franchise of commercial medications led by Poly-Vi-Flor® (multivitamin